Pneumoconiosis is a restrictive and occupational lung disease caused by inhalation of dust. There are a number of different agents that, when inhaled, can potentially cause pneumoconiosis. Organic and inorganic agents are responsible for causing this diseases. According to the Centers for Disease Control and Prevention, in 2013, 260,000 deaths occurred due to pneumoconiosis. Increasing prevalence of pneumoconiosis, increasing smoking population, and rising air pollution have driven the growth of the market. Approximately 75% of non-asbestos pneumoconiosis cases recorded under the IIDB scheme in 2009 were from individuals that are over 65 years. According to the Centers for Disease Control and Prevention, cigarette smoking is the leading cause of death in the United States, accounting for over 480,000 deaths every year. Moreover, increasing geriatric population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of pneumoconiosis; more than 60% of the global population smokes, this has increased the risk of pneumoconiosis and contributed in the growth of the market. However, side effects associated with the treatment and lack of long term treatment may lead to hinder the growth of the market.
The global pneumoconiosis market analysis by MRFR expected the market to grow at a CAGR of 6.8% during forecast period.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4639
Regional Analysis
The Americas dominate the global pneumoconiosis market owing to a large patient population, strong government support for research & development, and high healthcare spending. Smoking increase the risk of causing this disease. According to the Centers for Disease Control and Prevention, in 2015, about 15 in every 100 U.S. adults aged over 18 years smoked cigarettes. Which is estimated around 36.5 million adults in the United States currently smoke cigarettes. Moreover, changing lifestyle and increasing number of smokers has fuelled the growth of the market.
Europe has the second leading market in global pneumoconiosis market which is followed by Asia Pacific. Asia Pacific is the fastest growing market for pneumoconiosis. As per statistics, more than half of the china population smoke. China and India contribute a major share in the Asia Pacific pneumoconiosis market. Increasing geriatric population and increasing air pollution in this region have fuelled the growth of the market.
The Middle East and Africa contribute the least in the growth of global pneumoconiosis market. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition. However the growth of the Africa market is high due to the presence of opportunities for the development of the market.
Segmentation
The global pneumoconiosis market is segmented on the basis of types, causes, therapy, and end users.
On the basis of type, the market is segmented into asbestosis, berylliosis, byssinosis, coal workers pneumoconiosis, silicosis, and others.
On the basis of cause, the market is categorized into organic dusts, non-organic substances, and others. Organic substances are further segmented into hay, malt, mushrooms, and others. Non organic substances are further segmented into sulphur dioxide, ammonia, nitrogen dioxide, and others.
On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest X-ray, CT scan, and others. Treatment is further classified into mucolytic agent, antibiotic, and others.
On the basis of end user, the market is segmented into hospital, clinics, and others.
Key Players
The key players for the global pneumoconiosis market Abbott (US) Eli Lilly (US), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Novartis (Switzerland), Abbott (US), AstraZeneca (UK), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), and Bayer Cropscience Ltd. (U.S.).
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/pneumoconiosis-market-4639
Apraxia Market HighlightsThere are several types of apraxia such as ideomotor apraxia, ideational/conceptual apraxia, buccofacial or orofacial apraxia, constructional apraxia, apraxia of speech, and others.
Moreover, 12% of the population including children have migraine problem.
Mostly migraine occurs at the age of 25-55, which, in turn, is projected increase the Apraxia Market growth.Increasing prevalence of neurological disorder like apraxia, epilepsy, rising need for better treatment, increasing investment in biotechnology and pharmaceutical industries in R, and availability of funds drive the growth of the market.
The increasing focus of various government agencies on treating neurological disorders such as epilepsy, depression, and heart attacks may have a positive impact on the growth of the market.
Japan holds the major share of the regional market due to the availability of technology and huge healthcare spending.
Rapidly developing the economy, increasing healthcare expenditure, and government initiatives for research & development may drive the market in China and India over the assessment period.
Global Epilepsy Diagnosis & Treatment Market Research Report, By Type (Idiopathic, Cryptogenic, Symptomatic), Diagnosis (Neurological Exam, Blood Test, Imaging), Treatment (Medication, Surgery) End-User (Hospitals, Clinics) - Global Forecast Till 2027Market HighlightsIncreasing prevalence of epilepsy, rising number of traumatic brain injury cases, growing geriatric population, and rising healthcare expenditures are the major drivers for the global epilepsy diagnosis and treatment market.
However, high cost of therapeutic surgeries, low per capita healthcare expenditure, and lack of awareness for the disease in emerging economies are estimated to restrain the market growth during the projected period.
The imaging segment is sub-segmented into electroencephalogram, computerized tomography, magnetic resonance imaging, positron emission tomography, and others.
On the basis of treatment, the market is segmented into medication, surgery, brain stimulation, and others.
The brain stimulation segment is sub-segmented into deep brain stimulation, responsive neurostimulation, and others.
On the basis of end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/5647Regional AnalysisThe Americas dominate the global epilepsy diagnosis and treatment market, which can be attributed to the presence of a well-developed healthcare sector and huge patient population within the region.
Detecting diseases at earlier stages can positively impact the further clinical procedures and shorten the recovery span for patients. Global healthcare organizations as well as independent clinical bodies have intensified the processes of adopting optimal medical imaging equipment. The prime benefit of using efficient diagnostic imaging equipment is that it enables medical practitioners in identifying abnormalities at a stage where the disorder hasn’t matured to incurable or fatal levels. At present, medical imaging equipment can be regarded as a viable method for diagnosis of malignant ailments such as cancer and other tumor-related diseases. As cardiovascular diseases and cancer are among the most dominant disorders inciting use of advanced diagnostics, the global medical imaging equipment market was valued at US$ 29.4 Bn in 2015 and is projected to reach US$ 45.3 Bn by 2023, expanding at a CAGR of 5.6% during the forecast period from 2015 to 2023.
Report For Report Sample with Table of Contents@https://www.researchreportinsights.com/report/sample/110114733/Medical-Imaging-Equipment-Market
Improving the imaging accuracy will remain the key aspect that will determine the trajectory of developing medical imaging equipment for future. Anticipating disorders that are more likely to hamper human health in the upcoming decades has an equally influencing effect on such developments. The most recent technological advancement in diagnostic imaging is the use of electromagnetic radiation for producing images of internal human anatomy. Implementing tomography or similar 3D imaging techniques can be observed as the first step towards manufacturing futuristic medical imaging equipment. Crucial prospects that will shape up the future of medical imaging equipment include,
Miniaturization: The size of medical imaging equipment has been a predominant challenge in diagnostic operations. Replacing the large MRI and CT scanners with miniaturized devices will be a major achievement, not only for diagnostic purposes but also for boosting the revenues from detection procedures. Without curbing the efficiency, miniaturized medical imaging equipment will gain traction over existing ones. The competitive production costs and affordable diagnosis charges will promote the use of miniaturized imaging devices in the future.
Request For Report Discount@https://www.researchreportinsights.com/report/discount/110114733/Medical-Imaging-Equipment-Market
Portability: Reducing the equipment dimensions will invite opportunities for developing portable imaging devices. Stationary medical imaging equipment are generally preferred by surgeons as they are connected to ample power supply and prevent imaging implications due to mechanical shocks. Nevertheless, the advent of portable imaging devices will not only increase access to diagnostic technologies among rural areas, but also shorten the working time for clinical procedures. Using portable imaging equipment for diagnostic purposes in untapped regions will increase awareness of detecting diseases at initial stages. And, the operational hours of tedious diagnostic procedures may get abridged when images of the affected anatomical area are produced with such conveniently moving imaging equipment; unlike immovable imaging equipment that consume a lot of precious time.
Impact of Digitization: Calibrating the images is likely to get simpler in the years to come. Digitization can augment measurement processes and boost the accuracy. Calibrating molecular mutations in a tumor can help incision of antibodies in such molecules. The outbreak of tumorous pathogens can be curtailed when produced images are available in digitized measurements that identify even the subatomic alterations during diagnosis of living tissues.
Hybridization of Technologies: It is relatively possible for future imaging equipment to have an alternative of shifting among technologies. For example, an equipment developed with tomographic technology can amalgamate other contemporary technologies. Successful clinical adoption of non-ionizing imaging modalities such as ultrasound or optical is anticipated to be the forthcoming advancement in imaging technologies. Such hybrid imaging technologies will increase the revenues due to lack of radiation exposure, compared to tomographic and radiographic medical imaging technologies.
Key participants in global imaging equipment market include, GE Healthcare, Shimadzu Corporation, Philips Healthcare, Genesis Medical Imaging inc., Hologic Inc., Siemens Healthcare, Samsung Medison Co. Ltd, Carestream Health Inc., Hitachi Medical Corporation, Fujifilm Holdings Corporation, Toshiba Corporation and Fonar Corporation. The medical imaging equipment market is highly capital.
Report Analysis@https://www.researchreportinsights.com/report/rd/110114733/Medical-Imaging-Equipment-Market
